keyword
MENU ▼
Read by QxMD icon Read
search

Ocriplasmine

keyword
https://www.readbyqxmd.com/read/28857483/intravitreal-gas-for-symptomatic-vitreomacular-adhesion-a-synthesis-of-the-literature
#1
REVIEW
James E Neffendorf, Andrew R H Simpson, David H W Steel, Riti Desai, Dominic A McHugh, Edward Pringle, Timothy L Jackson
Symptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to foveal damage from vitreomacular traction (VMT) and includes isolated VMT, impending macular hole (MH), and full-thickness MH with persisting vitreous attachment. Management options include pars plana vitrectomy (PPV), intravitreal ocriplasmin, intravitreal gas injection or observation. This synthesis of the literature aimed to assess the safety and efficacy of intravitreal gas for sVMA. Articles describing patients with VMT or MH treated with intravitreal expansile gas were selected by systematic literature review using MEDLINE, EMBASE, and the Cochrane Database of Controlled Trials (CENTRAL) up to September 2016...
August 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28791829/intravitreal-ocriplasmin-a-breakthrough-in-the-treatment-of-vitreomacular-traction
#2
REVIEW
Anna E Mec-Słomska, Joanna Adamiec-Mroczek, Ewa Kuźmicz, Marta Misiuk-Hojło
Vitreoretinal interface pathologies, such as vitreomacular traction syndrome, epiretinal membranes and macular holes are sight-threatening conditions and one of the important causes of vision defects and vision loss. To this date, vigilance with observation of how the vitreomacular traction resolves, or vitreoretinal surgery in more severe cases, were the only treatment options. Recent rapid progress in ophthalmology, especially in diagnostic and visualization techniques, provided better insight into the mechanisms taking place on the vitreoretinal surface, which enabled a more accurate selection of treatment options...
May 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28767551/ocriplasmin-for-vitreomacular-traction-looking-outside-the-macula-a-wide-field-optical-coherence-tomography-study
#3
Matteo G Cereda, Chiara Preziosa, Isabella DʼAgostino, Mariano Cozzi, Ferdinando Bottoni, Marco Pellegrini, Andrea Giani, Giovanni Staurenghi
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer retinal layers outside the macula after intravitreal ocriplasmin injection. To study the relation between vitreous detachment and attenuation of retinal outer segments signal. METHODS: Retrospective cases series of 15 eyes. Each eye was scanned with the 55° wide-field optical coherence tomography lens in 6 different locations, three horizontal B-scan (central, temporal, and nasal) and three vertical B-scan (central, superior, and inferior) at baseline, 1 week, 1 month, 3 months, and 6 months after injection...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28755165/assessment-of-intravitreal-ocriplasmin-treatment-for-vitreomacular-traction-in-clinical-practice
#4
Ricarda G Schumann, Julian Langer, Denise Compera, Katharina Luedtke, Markus M Schaumberger, Thomas Kreutzer, Wolfgang J Mayer, Armin Wolf, Siegfried G Priglinger
PURPOSE: To assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or without full-thickness macular hole (FTMH), in real-life setting. METHODS: This is a monocentric, retrospective, consecutive series of 82 eyes from 82 patients who underwent ocriplasmin treatment between July 2013 and December 2016. We included 57 eyes with pure VMT, 17 eyes with small FTMHs, and eight eyes with medium FTMHs. Primary outcome measures were VMT release and MH closure rates...
July 28, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28699051/-assessing-the-added-benefit-of-new-ophthalmic-drugs-which-additional-insights-can-be-extracted-from-the-early-benefit-assessment
#5
REVIEW
M Appelrath, G Glaeske
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added benefit, limited for 5 years) and another agent, idebenone, received an added benefit due to its orphan drug designation (proof of a not quantifiable added benefit, limited for 2 years)...
July 11, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28681138/ocriplasmin-treatment-for-vitreomacular-traction-in-real-life-can-the-indication-spectrum-be-expanded
#6
Kleanthis Manousaridis, Silvia Peter-Reichart, Stefan Mennel
PURPOSE: To evaluate the efficacy of intravitreal ocriplasmin for the resolution of vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) in the clinical setting and to assess whether the indication spectrum of this treatment modality can be expanded beyond that of the MIVI-TRUST trials. METHODS: The records of patients with VMT with or without FTMH, who were treated with intravitreal ocriplasmin were reviewed. Patients were divided in two groups...
July 5, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28599332/-efficacy-and-safety-profile-of-ocriplasmin-treatment-an-update
#7
Denise Compera, Siegfried Priglinger, Ricarda Gisela Schumann
Pharmacological vitreolysis with ocriplasmin is an effective treatment option for eyes with vitreomacular traction. Pre-marketing and post-marketing clinical studies revealed an improvement of visual function in ocriplasmin treated eyes and showed a release of traction in up to 78% of cases. Treatment success is related to patient selection based on positive predictive factors. Adverse events, such as visual acuity loss, dyschromatopsia or photopsia are known to be self-limited in the majority of eyes. Structural outer retinal layer changes, such as ellipsoid zone disturbances or subretinal fluid accumulation on SD-OCT analysis, as well as ERG abnormalities, are transient and correlated to VMT release...
June 9, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28596997/the-charles-schepens-lecture-management-options-for-vitreomacular-traction-use-an-individualized-approach
#8
Harry W Flynn, Nidhi Relhan
PURPOSE: To present the management options for vitreomacular traction (VMT) and to recommend an individualized approach to treatment selection. DESIGN: Presented at the American Academy of Ophthalmology Annual Meeting, 2016, Chicago, October 15, 2016 (The Charles Schepens Lecture). PARTICIPANTS: None. METHODS: Review of published literature and clinical trials. MAIN OUTCOME MEASURES: Visual and anatomic outcomes of various treatment options for VMT were reviewed...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28427074/enzymatic-vitreolysis-for-vitreomacular-traction-in-diabetic-retinopathy
#9
REVIEW
Stanislao Rizzo, Daniela Bacherini
Vitreomacular traction (VMT) is one of many possible factors involved in the etiology of diabetic macular edema (DME). Pharmacologic vitreoretinal separation is a potential alternative to vitrectomy for VMT in diabetic retinopathy. Small case series have been published on the use of enzymatic vitreolysis in tractional DME, and demonstrate that the enzymatic release of the posterior vitreous cortex is more likely following the injection of plasmin enzyme. Further prospective and randomized clinical trials are necessary to evaluate the clinical relevance of ocriplasmin for vitreomacular traction in diabetic retinopathy, and additional studies are needed to determine more accurately which patients might benefit most from this treatment and how often and at what concentration ocriplasmin should be administered...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28389700/the-predictability-of-ocriplasmin-treatment-effects-is-there-consensus-among-retinal-experts-results-from-the-export-study
#10
Thomas Bertelmann, Joachim Wachtlin, Stefan Mennel, Michael J Koss, Mathias M Maier, Ricarda G Schumann, Sara Kazerounian, Hanna Daniel, Steffen Schmitz-Valckenberg
PURPOSE: To evaluate the agreement and predictability of ocriplasmin treatment effects among retinal experts (raters) by assessment of retinal imaging data of eyes treated for vitreomacular traction in nine different centers in Germany and Austria. METHODS: Retrospective cohort study. Combined confocal near-infrared scanning laser ophthalmoscopy and spectral-domain optical coherence tomography images (Spectralis® device, Heidelberg Engineering GmbH, Germany) from 136 eyes of 135 subjects were reviewed by 14 raters using an internet-based grading database and a standardized questionnaire...
July 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28282697/-initial-clinical-experiences-using-ocriplasmin-for-the-treatment-of-vitreomacular-traction-with-or-without-a-macular-hole
#11
J Lenk, E Matthé, S Ventzke, L E Pillunat, D Sandner
Purpose In vitreomacular traction (VMT), there is abnormal adhesion between the vitreous cortex and the retina, especially in the fovea. Symptoms of VMT include metamorphopsia and a decrease in visual acuity. Since 2013, ocriplasmin (Jetrea®) has been approved for treatment of symptomatic vitreomacular traction with or without macular holes (≤ 400 µm). Methods We retrospectively examined twenty-three eyes of twenty-one patients who underwent intravitreal ocriplasmin treatment for symptomatic vitreomacular traction with or without macular holes...
March 10, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28282694/long-term-persistence-of-subfoveal-fluid-following-ocriplasmin-treatment-of-an-ftmh
#12
S Tschuppert, H Gerding
No abstract text is available yet for this article.
April 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28264098/intravitreally-injected-fluid-dispersion-importance-of-injection-technique
#13
Koen Willekens, Geert Reyns, Marjan Diricx, Marc Vanhove, Bernard Noppen, Walter Coudyzer, Yicheng Ni, Jean H M Feyen, Peter Stalmans
Purpose: The purpose of this study was to evaluate the dispersion of intravitreally injected solutions and investigate the influence of varying injection techniques. Methods: This was a prospective study using enucleated porcine eyes and ultra-high-resolution computed tomography (UHRCT) scanning to visualize iomeprol intravitreal dispersion. Sixty eyes were divided over 12 different groups according to the injection procedure: fast (2 seconds) or slow (10 seconds) injection speed and needle tip location (6- and 12-mm needle shaft insertion or premacular tip placement verified by indirect ophthalmoscopy)...
March 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28198785/evaluation-of-full-field-electroretinogram-reductions-after-ocriplasmin-treatment-results-of-the-oasis-trial-erg-substudy
#14
David G Birch, Matthew S Benz, Daniel M Miller, Andrew N Antoszyk, Joseph Markoff, Petra Kozma, Esmeralda Meunier, Robert C Sergott
PURPOSE: To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial studying ocriplasmin. METHODS: The ERG substudy enrolled 62 of 220 OASIS subjects (randomized 2:1) and analyzed full-field electroretinograms and their association with both vitreomacular adhesion resolution and best-corrected visual acuity from baseline through Month 24...
February 14, 2017: Retina
https://www.readbyqxmd.com/read/28133919/visual-function-response-to-ocriplasmin-for-the-treatment-of-vitreomacular-traction-and-macular-hole
#15
Timothy L Jackson, Thomas Verstraeten, Luc Duchateau, Benedicte Lescrauwaet
PURPOSE: To assess the effect of an intravitreal ocriplasmin injection on visual function, measured using visual acuity (VA) and vision-related quality of life. METHODS: Post hoc analysis of prespecified secondary end-points in two multicentre, randomized, double-masked, phase 3 clinical trials. A total of 652 participants with symptomatic vitreomacular adhesion were enrolled, of whom 464 received a single intravitreal injection of 125 μg ocriplasmin and 188 received a single intravitreal placebo injection...
January 30, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28106706/intravitreal-ocriplasmin-in-clinical-practice-predictors-of-success-visual-outcomes-and-complications
#16
Henry L Feng, Daniel B Roth, Aisha Hasan, Howard F Fine, H Matthew Wheatley, Jonathan L Prenner, Sumit P Shah, Kunjal K Modi, William J Feuer
PURPOSE: To investigate predictors of success, visual outcomes, and complications of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular adhesion in a clinical care setting. METHODS: Retrospective chart review of 49 consecutive eyes of 47 patients who received intravitreal ocriplasmin. Spectral domain optical coherence tomography scans were examined for vitreomacular traction (VMT) release, full-thickness macular hole (FTMH) closure, and other changes in retinal anatomy...
January 18, 2017: Retina
https://www.readbyqxmd.com/read/28098729/vitrectomy-for-persistent-macular-holes-following-ocriplasmin-injection-a-comparative-multicenter-study
#17
Ricarda G Schumann, Armin Wolf, Hans Hoerauf, Albrecht Lommatzsch, Mathias Maier, Joachim Wachtlin, Michael J Koss, Thomas Kreutzer, Thomas Bertelmann, Sara Kazerounian, Stefan Mennel, Siegfried G Priglinger
PURPOSE: To determine functional and anatomical outcomes of pars plana vitrectomy for persistent full-thickness macular hole (MH) after intravitreal injection of ocriplasmin. METHODS: This is a multicenter retrospective interventional study of 37 eyes of 37 patients who underwent pars plana vitrectomy with internal limiting membrane peeling for persistent MH after ocriplasmin treatment between December 2013 and December 2015 and comparison with 35 eyes of 35 patients who were offered ocriplasmin injection but underwent pars plana vitrectomy alone without pharmacologic vitreolysis before surgery...
January 16, 2017: Retina
https://www.readbyqxmd.com/read/28033236/longitudinal-microperimetry-evaluation-after-intravitreal-ocriplasmin-injection-for-vitreomacular-traction
#18
Andrea Cacciamani, Aldo Gelso, Joseph M Simonett, Guido Ripandelli, Marco Pileri, Mario Stirpe, Fabio Scarinci
PURPOSE: To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin treatment in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction and relatively preserved baseline best-corrected visual acuity (BCVA). METHODS: Patients with vitreomacular traction received a single 125-μg intravitreal ocriplasmin injection and were followed longitudinally for 6 months with optical coherence tomography, BCVA testing, and microperimetry...
December 28, 2016: Retina
https://www.readbyqxmd.com/read/28005718/proportion-of-patients-with-macular-hole-surgery-who-would-have-been-favorable-ocriplasmin-candidates-a-retrospective-analysis
#19
Khurram Chaudhary, Michael Y K Mak, Robert Gizicki, Rajeev H Muni, David T Wong, Filiberto Altomare, Alan R Berger
PURPOSE: To identify favorable ocriplasmin candidates from a cohort of idiopathic full thickness macular hole surgery patients. METHODS: The records of patients with full thickness macular hole who underwent pars plana vitrectomy surgery between 2011 and 2015 were reviewed. Clinical data collected included patient demographics, pre- and post-operative Snellen visual acuity, optical coherence tomography findings, and lens status. The authors defined "favorable" ocriplasmin candidates as patients with focal vitreomacular traction, no epiretinal membrane, and hole size ≤400 μm...
January 2017: Retina
https://www.readbyqxmd.com/read/27990054/ocriplasmin-for-vitreomacular-traction
#20
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Australian Prescriber
keyword
keyword
81636
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"